Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I van der Lee

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2003
Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatmentK W Maas, I van der Lee, K Bolt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2001
Single-agent gemcitabine in patients with resistant small-cell lung cancerI van der Lee, E F Smit, J W van Putten, et al.
Respiratory Medicine|July 10, 2009
Nitric oxide diffusing capacity versus spirometry in the early diagnosis of emphysema in smokersI van der Lee, H A Gietema, P Zanen, et al.
Frontiers in Immunology|March 28, 2025
Mutated <i>DNMT3A</i> creates a public HLADQ- binding neoantigen on acute myeloid leukemiaDyantha I van der Lee, Eva M Argiro, Sebastiaan N J Laan, et al.
Biomedicines|May 25, 2024
Hotspot DNA Methyltransferase 3A (<i>DNMT3A</i>) and Isocitrate Dehydrogenase 1 and 2 (<i>IDH1/2</i>) Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for ImmunotherapyNadine E Struckman, Rob C M de Jong, M Willy Honders, et al.
Frontiers in Immunology|May 5, 2020
Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility AntigensKyra J Fuchs, M Willy Honders, Edith D van der Meijden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2016
Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2Margot J Pont, Dyantha I van der Lee, Edith D van der Meijden, et al.
The Journal of Clinical Investigation|January 15, 2019
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemiaDyantha I van der Lee, Rogier M Reijmers, Maria W Honders, et al.
Leukemia|December 13, 2025
A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemiaNadine E Struckman, Georgia Koutsoumpli, Rob C M de Jong, et al.
Cancers|November 13, 2021
An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AMLDyantha I van der Lee, Georgia Koutsoumpli, Rogier M Reijmers, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2003
Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatmentK W Maas, I van der Lee, K Bolt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2001
Single-agent gemcitabine in patients with resistant small-cell lung cancerI van der Lee, E F Smit, J W van Putten, et al.
Respiratory Medicine|July 10, 2009
Nitric oxide diffusing capacity versus spirometry in the early diagnosis of emphysema in smokersI van der Lee, H A Gietema, P Zanen, et al.
Frontiers in Immunology|March 28, 2025
Mutated <i>DNMT3A</i> creates a public HLADQ- binding neoantigen on acute myeloid leukemiaDyantha I van der Lee, Eva M Argiro, Sebastiaan N J Laan, et al.
Biomedicines|May 25, 2024
Hotspot DNA Methyltransferase 3A (<i>DNMT3A</i>) and Isocitrate Dehydrogenase 1 and 2 (<i>IDH1/2</i>) Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for ImmunotherapyNadine E Struckman, Rob C M de Jong, M Willy Honders, et al.
Frontiers in Immunology|May 5, 2020
Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility AntigensKyra J Fuchs, M Willy Honders, Edith D van der Meijden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2016
Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2Margot J Pont, Dyantha I van der Lee, Edith D van der Meijden, et al.
The Journal of Clinical Investigation|January 15, 2019
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemiaDyantha I van der Lee, Rogier M Reijmers, Maria W Honders, et al.
Leukemia|December 13, 2025
A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemiaNadine E Struckman, Georgia Koutsoumpli, Rob C M de Jong, et al.
Cancers|November 13, 2021
An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AMLDyantha I van der Lee, Georgia Koutsoumpli, Rogier M Reijmers, et al.
Pageof 2